Clinical trial
Potential Impact (Benefit) of Preventative Treatment With Topamax on the…
NCT00210496 · Janssen-Ortho LLC, Industry · Completed
Key facts
| NCT number | NCT00210496 |
|---|---|
| Title | Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine |
| Official title | Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) |
| Lead sponsor | Janssen-Ortho LLC, Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Migraine, Classic Migraine, Common Migraine |
| Intervention type | Drug |
| Interventions | topiramate, almotriptan malate |
| Enrollment | 406 |
| Start date | Jun 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: